Ugeskr Læger 2017;179:V05170365
Immunotherapy is cancer treatment with a novel side-effect profile
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors – anti-cyto-toxic T-lymphocyte-associated-4 antibodies and anti-programmed cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term sequelae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.